Indivior PLC (NASDAQ:INDV) Forecasted to Post Q2 2024 Earnings of $0.46 Per Share

Indivior PLC (NASDAQ:INDV) – Equities research analysts at Northland Capmk dropped their Q2 2024 earnings per share estimates for Indivior in a research report issued on Thursday, April 25th. Northland Capmk analyst C. Byrnes now anticipates that the company will earn $0.46 per share for the quarter, down from their prior forecast of $0.47. The consensus estimate for Indivior’s current full-year earnings is $2.03 per share. Northland Capmk also issued estimates for Indivior’s Q3 2024 earnings at $0.53 EPS and Q4 2024 earnings at $0.58 EPS.

Separately, Craig Hallum initiated coverage on shares of Indivior in a research report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 target price for the company.

Indivior Stock Up 1.9 %

INDV opened at $17.58 on Monday. Indivior has a twelve month low of $14.38 and a twelve month high of $26.50. The firm has a 50 day moving average price of $20.49 and a 200-day moving average price of $18.29. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 1,758.00 and a beta of 0.46.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.15. The business had revenue of $293.00 million during the quarter, compared to analyst estimates of $260.00 million. Indivior had a return on equity of 700.00% and a net margin of 0.44%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Indivior by 15.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,596 shares of the company’s stock valued at $860,000 after buying an additional 5,365 shares during the last quarter. Mackenzie Financial Corp raised its holdings in Indivior by 0.3% in the 3rd quarter. Mackenzie Financial Corp now owns 562,595 shares of the company’s stock worth $12,979,000 after purchasing an additional 1,909 shares during the period. Swiss National Bank raised its holdings in Indivior by 1.0% in the 3rd quarter. Swiss National Bank now owns 287,897 shares of the company’s stock worth $6,257,000 after purchasing an additional 2,727 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Indivior during the third quarter valued at $801,000. Finally, Liontrust Investment Partners LLP bought a new stake in Indivior during the third quarter valued at about $43,340,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.